Fantasy Football Rankings ft. Martavis Bryant and his road to WR1

If you somehow don’t know Martavis Bryan he has been a highlight for the Steelers when he was brought on the team. Bryant has a wicked fast 40-yard dash, crazy hands, strong field vision, and a pretty big boost in fantasy football rankings in 2014. The real question is why isn’t he on WR1? It comes down to one thing, play time.

Bryant has only played 24 games in three years! He has been suspended multiple times due to failed drug screens. His second failed drug screen cost him the entire 2016 season. He wasn’t helping the fantasy football rankings for 2016, that’s for sure. Martavis Bryant has a 25% TD to reception rate on his record and he shows promise to be a great WR. IF he plays 16 more games he should be able to nail WR1 and boost fantasy football rankings again.

Fantasy football leagues are built to challenge your friends and the country in a battle of football knowledge and intuition. Fantasy football rankings help you decide which players to put on your fantasy team and run your team to the playoffs.

 

Clay Siegall concentrates on improving cancer survivability

The major cancer breakthroughs of the 20th century took place in the decades of the ‘30s and ‘40s. Prior to that, most people who got cancer had a very poor chance of surviving much more than about 1 year. The five-year survival rates for many types of cancers were dismally low, with nearly all patients who contracted those diseases dying prior to the end of that period.

That all began to change, with the advent of radiation and chemotherapy as viable means of treating certain types of cancer. In fact, nearly all cancer types benefited substantially from the development of chemotherapy and radiation. However, certain types of cancers, such as breast cancer, melanoma and colon cancer, saw dramatic improvements in survivability. This was doubly true with the refinement of surgical excision techniques, which began becoming a far more viable means of not just treating cancer but curing it.

However, the vast gains in survivability that were seen between the 1930s and 1960s were essentially confined to that era. Between approximately 1950 and 1990, few cancer types saw real gains in survivability. The stagnation was largely due to the vast majority of gains in survivability being attributable to the three major treatment breakthroughs of radiation, chemotherapy and improved surgical techniques. For many types of cancer, the five-year survival rates in 1990 were little different than they were in 1950.

 

Clay Siegall, one of the nation’s leading cancer researchers, decided to do something about the stagnation in the five-year survival rates of many types of cancers. In 1998, he founded Seattle Genetics, a company dedicated to developing new drugs for cancer subtypes that have not seen substantial mortality improvements over the last three to five decades.

The company’s first FDA-approved drug, ADCetris, is an antibody drug conjugate certified for the treatment of refractory non-Hodgkin’s lymphoma. This innovative drug has dramatically improved patient outcomes for the subset of non-Hodgkin’s lymphoma sufferers who are not responding well to first line treatments. With this drug, Dr. Siegall has saved thousands of lives.

 

A Unique Acquisition for Equities First Holdings

Equities First Holdings, one of the leading advisory and investment firms around the world, was first established in 2012 in London, United Kingdom, where today it has its central office. From the very beginning, Equities First Holdings has been geared at providing sound investment advice to its clients, and has, over the years, built a very substantial portfolio by doing this. Today, the portfolio of Equities First Holdings consists of many startup companies around the world, as well as some of the most prominent investment banks operating today. Equities First Holding was originally known as Meridian Equity Partners Limited, before being acquired by the company to which it shares its name today.

The merger between the two companies took Equities First Holdings to the next level, as there are now offices located around the world, in places such as Europe, Asia, as well as Australia. The merger also allowed for Equities First Holdings to increase their offices in the United States. Through Equities First Holdings’ rapid expansion, many of the branches of the company have seen an incredible increase in stability and have now been operating almost independently. The final step in creating the new Equities First Holdings was to pay back shares that were used as collateral for the initial deal. An announcement was recently made that those shares, which numbered 9,786,580, 1,500,000 of which were part of a reimbursement deal, would be returned to Mr. Joel Leonoff, of Paysafe Group PLC on May 2, 2017.

More Visit: https://bloghelpline.com/notable-achievements-equities-first-holdings-llc/